Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 8/20 | 0.46 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | F10 | P00742 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6763988 | 0.92 | BDKRB1 (0.43) | BDKRB1RORCMAPK1USP2TP53 | |
| SCHEMBL6764167 | 0.90 | BDKRB1 (0.56) | BDKRB1TSHR | |
| SCHEMBL5118176 | 0.87 | BDKRB1 (0.47) | BDKRB1RORCMAPK1F10CYP11B2 | |
| SCHEMBL6760000 | 0.87 | BDKRB1 (0.46) | BDKRB1DRD2DRD4DRD3 | |
| SCHEMBL6764313 | 0.86 | USP2 (0.35) | BDKRB1RORCF10USP2TP53 | |
| SCHEMBL5110833 | 0.85 | BDKRB1 (0.46) | BDKRB1RORCMAPK1F10CYP11B2 | |
| SCHEMBL5111153 | 0.85 | BDKRB1 (0.57) | BDKRB1RORCF10 | |
| SCHEMBL6764163 | 0.84 | BDKRB1 (0.42) | BDKRB1MAPK1 | |
| SCHEMBL6761752 | 0.84 | BDKRB1 (0.54) | BDKRB1TP53 | |
| SCHEMBL6762456 | 0.83 | BDKRB1 (0.61) | BDKRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063725-A1 | Novel n(phenylsulphonyl)glycine derivatives and their therapeutic use | LABORATORIES FOURNIER S.A. (FR) | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063725-A1 | Novel n(phenylsulphonyl)glycine derivatives and their therapeutic use | GLS, GLS2, GLRB | BDKRB1 481/4885RORC 3349/4885MAPK1 3459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.